|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Center MM, Jemal A, Lortet-Tieulent J,
Ward E, Ferlay J, Brawley O and Bray F: International variation in
prostate cancer incidence and mortality rates. Eur Urol.
61:1079–1092. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bell KJ, Del Mar C, Wright G, Dickinson J
and Glasziou P: Prevalence of incidental prostate cancer: A
systematic review of autopsy studies. Int J Cancer. 137:1749–1757.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Brawley OW: Prostate cancer epidemiology
in the United States. World J Urol. 30:195–200. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sanso JF, Soberate S, Alonso GP and Torres
VRM: Mortality from cancer in Cuba. Revista Cubana de Salud
publica. 36:78–94. 2010.
|
|
6
|
MINSAP: Dirección de registros médicos y
estadísticas de salud. Anuario estadístico de salud. La Habana:
52-68, 2018 (In Spanish). Access date March 16, 2020.
|
|
7
|
SEER database of epidemiological
surveillance in the EEUU, 2008-2014. urihttps://seer.cancer.gov/archive/csr/1975_2014/results_merged/sect_23_prostate.pdfsimplehttps://seer.cancer.gov/archive/csr/1975_2014/results_merged/sect_23_prostate.pdf.
Access date March 16, 2020.
|
|
8
|
Mohler JL, Armstrong AJ, Bahnson RR,
D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano
CS, Horwitz EM, et al: Prostate cancer, version 1.2016. J Natl
Compr Canc Netw. 14:19–30. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
European Association of Urology. Mottet N,
Bellmunt J, Briers E, Bolla M, Bourke L, Cornford P, et al.
Guidelines on Prostate Cancer, 2017. EAU Guidelines. ISBN
978-90-79754-91-5.urihttps://uroweb.org/wp-content/uploads/09-Prostate-Cancer_2017_web.pdfsimplehttps://uroweb.org/wp-content/uploads/09-Prostate-Cancer_2017_web.pdf.
Access date March 16, 2020.
|
|
10
|
Epstein JI, Egevad L, Amin MB, Delahunt B,
Srigley JR and Humphrey PA: Grading Committee: The 2014
International Society of Urological Pathology (ISUP): Consensus
conference on Gleason grading of prostatic carcinoma: Definition of
grading patterns and proposal for a new grading system. Am J Surg
Pathol. 40:244–252. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Amin MB, Edge S, Greene F, Byrd DR,
Bokland RK, Washington RK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC et al, (eds). AJCC Cancer Staging Manual, 8th
ed. Springer International Publishing, Berlin, 2017.
|
|
12
|
Devlin HL and Mudryj M: Progression of
prostate cancer: Multiple pathways to androgen independence. Cancer
Lett. 274:177–186. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Leibowitz-Amit R and Joshua AM: Targeting
the androgen receptor in the management of castration-resistant
prostate cancer: Rationale progress and future directions. Cur
Oncol. 19 (Suppl 3):S22–S31. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Montgomery RB, Mostaghel EA, Vessella R,
Hess DL, Kalhorn TF, Higano CS, True LD and Nelson PS: Maintenance
of intratumoral androgens in metastatic prostate cancer: A
mechanism for castration-resistant tumor growth. Cancer Res.
68:4447–4454. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Michaud JE, Billups KL and Partin AW:
Testosterone and prostate cancer: An evidence-based review of
pathogenesis and oncologic risk. Ther Adv Urol. 7:378–387.
2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512.
2004.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Moro Soria A, Laborí Cardá C, López AB and
Hernández JG: El cáncer de próstata resistente a castración.
Mecanismos de progresión y nuevos tratamientos. Rev Cub Urol.
1:106–122. 2012.(In Spanish).
|
|
18
|
Oh B, Figtree G, Costa D, Eade T, Hruby G,
Lim S, Elfiky A, Martine N, Rosenthal D, Clarke S and Back M:
Oxidative stress in prostate cancer patients: A systematic review
of case control studies. Prostate Int. 4:71–87. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Khandrika L, Kumar B, Koul S, Maroni P and
Koul HK: Oxidative stress in prostate cancer. Cancer Lett.
282:125–136. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
García Triana BE, Saldaña Bernabeu A and
Saldaña García L: El estrés oxidativo y los antioxidantes en la
prevención del cáncer. Revista Habanera de Ciencias Médicas.
12:187–196. 2012.(In Spanish).
|
|
21
|
Vallejo-Zamudio E, Rojas-Velásquez A and
Torres-Bulgarin O: Una poderosa herramienta en la medicina
preventiva del cáncer: Los antioxidantes. El Residente. 12:104–111.
2017.(In Spanish).
|
|
22
|
Singh K, Bhori M, Arfat Y, Bhat G and
Marar T: Antioxidants as precision weapons in war against cancer
chemotherapy induced toxicity. Exploring the armory of obscurity.
Saudi Pharm J. 26:177–190. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Simone CB II, Simone NL, Simone V and
Simone CB: Antioxidants and other nutrients do not interfere with
chemotherapy or radiation therapy and can increase kill and
increase survival, part 2. Altern Ther Health Med. 13:40–47.
2007.PubMed/NCBI
|
|
24
|
González A, et al: Prevention and
antitumor treatment. In: Antiviral and Others Degenerative
Diseases. Pharmaceutical Laboratory Catalysis, S.L.(C/ Macarena 14,
Madrid, CP 28016). January 2001. Scientific Department. Unpublished
book. Available upon request to the laboratory.
|
|
25
|
Eficacia en cáncer del Oncoxin+Viusid.
Revista mundial de salud y medicina 176, 2014 (In Spanish). Access
date March 16, 2020.
|
|
26
|
Corte AM, Rodriguez E and Kobeleienky M:
Prospective open study on safety and effectiveness of supplement on
tumor L markers and quality of life in patients of cancer of the
prostate. Rev Solidaridad. Argentina, 2013.
|
|
27
|
Azzouni F and Mohler J: Biology of
castration-recurrent prostate cancer. Urol Clin North Am.
39:435–520. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Helfand BT and Catalon WJ: The
epidemiology and clinical implications of genetic variation in
prostate cancer. Urol Clin North Am. 41:277–297. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tomlins SA, Alshalalfa M, Davicioni E,
Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ,
et al: Characterization of 1577 primary prostate cancers reveals
novel biological and clinic pathologic insights into molecular
subtypes. Eur Urol. 68:555–567. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Klein EA, Cooperberg MR, Magi-Galluzzi C,
Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis
AC, et al: A 17-gene assay to predict prostate cancer
aggressiveness in the context of Gleason grade heterogeneity, tumor
multifocality, and biopsy undersampling. Eur Urol. 66:550–560.
2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Correa Zaporta D. Characterization of
patients with prostate cancer. Two consultories. Reyna Polyclinic.
Thesis General Integral Medicine Specialty 2016-2017 (not
publishable). General Calixto García University. Avenida
Universidad y J Plaza, Ciudad de la Havana, CP10400, Cuba (In
Spanish).
|
|
32
|
Rodríguez Borrego LD: Detección del cáncer
de próstata en la comunidad Policlínico Docente Wilfredo Santana.
Tesis Especialidad de Urología, La Habana. Rev Cub Urol.
7(e47)2018.
|
|
33
|
Borrego Díaz L, González Sapsin K, Borrego
Pino L, Dovale Borjas B and González Sapsin K: Diagnóstico tardío
del cáncer en adultos mayores en el hospital V. I. Lenin. Correo
Científico Médico de Holguín 12, 2018.
|
|
34
|
García PHA and Varela R: Validez
diagnóstica del antígeno prostático específico para la presencia de
metástasis en pacientes con cáncer de próstata. Urol Colomb.
19:13–18. 2010.
|
|
35
|
Salman JW, Schoots IG, Carlsson SV,
Jenster G and Roobol MJ: Prostate specific antigen as a tumor
marker in prostate cancer: Biochemical and clinical aspects. Adv
Exp Med Biol. 867:93–114. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Karnofsky DA, Abelarman WH, Graver LF and
Burchenal JH: The use of the nitrogen mustards in the palliative
treatment of carcinoma. With particular reference to bronchogenic
carcinoma. Cancer. 1:634–656. 1948.
|
|
37
|
Pérez-Cruz PE and Francisco Acevedo C:
Escalas de estado en cáncer. Gastroenterol Latinoam. 25:219–226.
2014.
|
|
38
|
Herrera-Guerrero MI, Torres Gómez A and
Allende Pereza S: Correlación del estado funcional de Karnofsky con
la supervivencia de pacientes con tumores de origen
gastrointestinal en un servicio de cuidados paliativos. Cir Gen.
36:134–137. 2014.
|
|
39
|
Petrylak DP: The current role of
chemotherapy in metastatic hormone-refractory prostate cancer.
Urology. 65 (Suppl 5):S3–S7, Discussion 7-8. 2005.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Petrylak DP, Tangen CM, Hussain MH, Lara
PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M,
et al: Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Berthold DR, Pond GR, Soban F, de Wit R,
Eisenberger M and Tannock IF: Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer: Updated
survival in the TAX 327 study. J Clin Oncol. 26:242–245.
2008.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zumsteg ZS, Spratt DE, Pei I, Zhang Z,
Yamada Y, Kollmeier M and Zelefsky MJ: A new risk classification
system for therapeutic decision making with intermediate-risk
prostate cancer patients undergoing dose-escalated external beam
radiation therapy. Eur Urol. 64:895–902. 2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
van Soest RJ and de Wit R: Irrefutable
evidence for use of docetaxel in newly diagnosed metastatic
prostate cancer: Result from de STAMPEDE and CHAARTER trials. BMC
Med. 13(304)2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Gravis G, Boher JM, Joly F, Soulié M,
Albiges L, Priou F, Latorzeff I, Delva R, Krakowski I, Laguerre B,
et al: Androgen deprivation therapy (ADT) plus docetaxel versus ADT
alone in metastatic non castrate prostate cancer: Impact of
metastatic burden and long-term survival analysis of the randomized
phase 3 GETUG-AFU15 trial. Eur Urol. 70:256–262. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Nguyen PL, Chen MH, Catalona WJ, Moul JW,
Sun L and D'Amico AV: Predicting prostate cancer mortality among
men with intermediate to high-risk disease and multiple
unfavourable risk factors. Int J Radiat Oncol Biol Phys.
73:659–664. 2009.PubMed/NCBI View Article : Google Scholar
|
|
46
|
James ND, Sydes MR, Mason MD, Clarke NW,
Dearnaley DP, Millman MRS, Parker C, Ritchie AW, Russell JM,
Staffurth J, et al: Docetaxel and/or zoledronic acid for
hormone-naive prostate cancer: First overall survival results from
STAMPEDE (NCT00268476). J Clin Oncol. 33 (Suppl)(5001)2015.
|
|
47
|
Van Poppel H and Tombal B: Chemoprevention
of prostate cancer with nutrient and supplement. Cancer Manag Res.
3:91–100. 2011.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Sarkar, et al: Perspective for cancer
prevention with natural component. Endocrin Relative Cancer.
17:R195–R212. 2010.
|
|
49
|
Amin AR, Kucuk O, Khuri FR and Shin DM:
Perspectives for cancer prevention with natural compounds. J Clin
Oncol. 27:2712–2725. 2009.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Coronado HM, Vega y León S, Gutiérrez TR,
Vázquez FM and Radilla VC: Antioxidantes: Perspectiva actual para
la salud humana. Rev Chil Nutr. 42:206–212. 2015.(In Spanish).
|
|
51
|
Heaney ML, Gardner JR, Karasavvas N, Golde
DW, Scheimberg DA, Smith EA and O'Connor OA: Vitamin C antagonizes
the cytotoxic effects of antineoplastic drug. Cancer Res.
68:8031–8038. 2008.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Roomi WM, Ivanov V, Kalinovsky T,
Niedzwiecki A and Rath M: In vivo antitumor effect of
ascorbic acid, lysine, proline and green tea extract on human colon
cancer cell HCT 116 xenograіs in nude mice: Evaluation of tumor
growth and immunohistochemistry. Oncol Rep. 13:421–425.29.
2005.PubMed/NCBI
|
|
53
|
Tang Y, Zhao DY, Elliot S, Zhao W, Curiel
TJ, Beckman BS and Burrow ME: Epigallocatechin-3 gallate induces
growth inhibition and apoptosis in human breast cancer cells
through surviving suppression. Int J Oncol. 31:705–711.
2007.PubMed/NCBI
|
|
54
|
Peng G, Dixon DA, Muga SJ, Smith TJ and
Wargovich MJ: Green tea polyphenol (-)-epigallocatechin-3-gallate
inhibits cyclooxygenasa-2 expression in colon carcinogenesis. Mol
Carcinog. 45:309–319. 2006.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Frömberg A, Gutsch D, Schulze D,
Vollbracht C, Weiss G, Czubayko F and Aigner A: Ascorbate exerts
anti-proliferative effects through cell cycle inhibition and
sensitizes tumor cells towards cystostatic drugs. Cancer Chemoter
Pharmacol. 67:1157–1166. 2011.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Ferriols Lisart R, Ferriols Lisart F, Alós
Almiñana M and Magraner Gil J: Calidad de vida en oncología
clínica. Farm Hosp. 19:315–322. 1995.
|
|
57
|
Marín Caro MM, Laviano A and Pichard C:
Nutritional intervention and quality of life in adult oncology
patients. Clin Nutr. 26:289–301. 2007.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Faria A, Coriat J, Rueda M, Cardona C and
Rosselli D: Nutritional supplements as modifiers of morbidity and
mortality in patients with cancer. Latin American Nutrition Files.
67:169–177. 2017.
|
|
59
|
Armstrong JA, Garrett-Mayer E, De Wit R,
Tannock I and Mario Eisenberger M: Prediction of survival following
first-line chemotherapy in men with castration-resistant metastatic
prostate cancer. Clin Cancer Res. 16:203–211. 2010.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Hernández-García S, González V, Sanz E and
Pandiella A: Effect of ocoxin oral solution in HER2-overexpressing
breast cancer. Nutr Cancer. 67:1159–1169. 2015.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Preciado-Estrella DA, Kaplan SA, Iturriaga
Goyón E, Ramón-Trejo E and Mayorga Gómez E: Auza Benavides A y
colaboradores: Comparación del Índice Internacional de Síntomas
Prostáticos versus Escala Visual Análoga Gea® para la
evaluación de los síntomas de la vía urinaria inferior. Rev Mex
Urol. 77:372–382. 2017.(In Spanish).
|
|
62
|
Bettuzzy S, Brauzi M, Rizzy F, Castagnetti
G, Peracchia G and Corti A: Chemoprevention of human prostate
cancer by oral administration of green catechins in volunteers with
high grade prostate intraepithelial neoplasm: A preliminary report
from a one year proof of principle study. Cancer Res. 66:1234–1240.
2006.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Márquez J, Mena J, Hernández-Unzueta I,
Benedicto A, Sanz E, Arteta B and Olaso E: Ocoxin® oral
solution slows down tumor growth in an experimental model of
colorectal cancer metastasis to the liver in balb/c mice. Oncol
Rep. 35:1265–1272. 2016.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Diaz-Rodriguez E, Hernández-Garcia S, Sanz
E and Pandiella A: Antitumor effect of ocoxin on acute myeloid
leukemia. Oncotarget. 7:6231–6242. 2016.
|
|
65
|
Diaz-Rodríguez E and Sanz E: Pandiella: A
Efecto antitumoral de Oncoxina un suplemento nutricional que
contiene compuestos naturales, en el cáncer de pulmón de células
pequeñas. Revista Internacional de Oncología. 5:113–123. 2018.
|
|
66
|
Parker C, Gillessen S, Heidenreich A and
Horwich A: ESMO Guidelines Committee: Cancer of the prostate: ESMO
Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 26 (Supl 5):v69–v77. 2015.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Wolf AM, Wender RC, Etzioni RB, Thompson
IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K,
et al: American cancer society guideline for the early detection of
prostate cancer: Update 2010. CA Cancer J Clin. 60:70–98.
2010.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Kontos CK, Adamopoulos PG and Scorilas A:
Prognostic and predictive biomarkers in prostate cancer. Expert Rev
Mol Diagn. 15:1567–1576. 2015.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Hussain M, Tangen CM, Higano C,
Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small
EJ, Donnelly B, et al: Absolute prostate-specific antigen value
after androgen deprivation is a strong independent predictor of
survival in new metastatic prostate cancer: Data from Southwest
Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 24:3984–3990.
2006.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Pérez-Peña J, Diaz-Rodríguez E, Sanz E and
Pandiella A: Papel Central de la regulación del ciclo celular en la
acción antitumoral de la oncoxina. Nutrients 11, 2019.
|
|
71
|
Amstrong AJ, Goerge DJ and Halbi S: Serum
lactate dehydrogenase (LDH) as a biomarker for survival with mTOR
inhibition in patients with metastatic renal cells carcinoma (RCC).
J Clin Oncol. 28 (Suppl 15)(S4631)2010.
|
|
72
|
Angulo J, Romero I, Díaz-Puente MT, Enrech
S, Díez R and Molina T: Supervivencia del cáncer de próstata
resistente a la castración en la práctica clínica y el papel del
tratamiento. Rev Colomb Cancerol. 21:95–103. 2017.
|
|
73
|
Schröder FH, Hugosson J, Roobol MJ,
Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H,
Zappa M, et al: Prostate-cancer mortality at 11 years of follow-up.
N Engl J Med. 366:981–990. 2012.PubMed/NCBI View Article : Google Scholar
|
|
74
|
de Bono JS, Scher HI, Montgomery RB,
Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ
and Raghavan D: Circulating tumor cells predict survival benefit
from treatment in metastatic castration-resistant prostate cancer.
Clin Cancer Res. 14:6302–6309. 2008.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Steyerberg EW, Moons KG, Vander Windt DA,
Hayden JA, Perel P, Schroter S, Riley RD, Hemingway H and Altman
DG: PROGRESS Group: Prognosis Research Strategy (PROGRESS) 3:
Prognostic model research. PLoS Med. 10(e1001381)2013.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Weiner AB, Matulewicz RS, Eggener SE and
Schaeffer EM: Increasing incidence of metastatic prostate cancer in
the United States (2004-2013). Prostate Cancer Prostatic Dis.
19:395–397. 2016.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Pérez BP, Corral JJ and Fernández de
Tejerina CMA: Neurotoxicidad por quimioterapia. Capitulo 6:
112-116.
|
|
78
|
Al Martin, UPA Rodríguez, LPA Rodríguez:
Manejo de la toxicidad neurológica Manual de la SEOM de cuidados
continuos, 2nd edition, pp 156. urihttp://www.seom.org/seomcms/images/stories/recursos/MANUAL_SEOM_CUIDADOS_CONTINUOS_Segunda_edicion.pdfsimplehttp://www.seom.org/seomcms/images/stories/recursos/MANUAL_SEOM_CUIDADOS_CONTINUOS_Segunda_edicion.pdf.
Access date March 16, 2020.
|
|
79
|
Hernández-Unzueta I, Benedicto A, Olaso E,
Sanz E, Viera C, Arteta B and Márquez J: Ocoxin oral
solution® as a complement to irinotecan chemotherapy in
the metastatic progression of colorectal cancer to the liver. Oncol
Lett. 13:4002–4012. 2017.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Uddin DM, Islam M, Mahmood I, Gosha AK,
Khatun RA and Kundu S: Findings of the 3-month supportive treatment
with Oncoxin solution beside the standard modalities of patients
with different neoplastic diseases. TAJ. 22:172–175. 2009.
|
|
81
|
Hernández-Unzueta I, Benedicto A, Romayor
I, Herrero A, Sanz E, Arteta B, Olaso E and Márquez J: Ocoxin oral
solutions exerts and antitumor effect in pancreatic cancer and
reduce the stromal mediated chemotherapy. Pancreas. 48:555–567.
2019.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Rivas CI, Alert SJ, Alfonso G, Candanedo
H, Cuervo Y, Mestre B, Cabello JR, Lence J, Lugoyo M and Sanz E:
Oncoxin-Viusid with radiotherapy and chemotherapy in patients with
head and neck cancer: Results from a phase II, randomised, double
blind study. J Cancer Sci Ther. 10(10)2018.
|
|
83
|
Lorente R, Duran D, Viamonte J, Lence AJ,
Reyes R and Sans E: Efficacy of Oncoxin-Viusid on the reduction of
adverse reactions to chemotherapy and radiotherapy in patients
diagnosed with cervical cancer and endometrial adenocarcinoma. J
Cancer Ther. 11:276–295. 2020.
|
|
84
|
Tan W: Promising new treatment option for
metastatic androgen independent prostate cancer. Actas Urol Esp.
31:680–685. 2007.(In Spanish). PubMed/NCBI View Article : Google Scholar
|
|
85
|
Huguet Pérez J, Maroto Rey P, Palou
Redorta J and Villavicencio Mavrich H: Hormone-refractory prostate
cancer. Modifications of the therapeutic strategies since
chemotherapy proved its usefulness. Actas Urol Esp. 30:123–133.
2006.(In Spanish). PubMed/NCBI View Article : Google Scholar
|
|
86
|
Berlin A and Fernández MI: Advances in the
treatment of castration-resistant prostate cancer: Emphasis in new
hormonal therapies. Rev Med Chile. 143:223–236. 2015.(In Spanish).
PubMed/NCBI View Article : Google Scholar
|
